See more : TCL Technology Group Corporation (000100.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Sunshine Biopharma, Inc. (SBFMW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sunshine Biopharma, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tongyu Heavy Industry Co., Ltd. (300185.SZ) Income Statement Analysis – Financial Results
- Grand Power Logistics Group Limited (8489.HK) Income Statement Analysis – Financial Results
- Intouch Holdings Public Company Limited (INTUCH.BK) Income Statement Analysis – Financial Results
- Serviceware SE (SJJ.DE) Income Statement Analysis – Financial Results
- Shradha Infraprojects Limited (SHRADHA.NS) Income Statement Analysis – Financial Results
Sunshine Biopharma, Inc. (SBFMW)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.sunshinebiopharma.com
About Sunshine Biopharma, Inc.
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.09M | 4.35M | 228.43K | 71.41K | 21.12K | 447.20K | 0.00 | 0.00 | 1.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.75M | 2.65M | 117.83K | 25.85K | 11.05K | 391.08K | 6.63K | 60.73K | 384.58K | 263.33K | 475.00K | 250.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 8.34M | 1.70M | 110.60K | 45.56K | 10.07K | 56.12K | -6.63K | -60.73K | -382.87K | -263.33K | -475.00K | -250.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 34.61% | 39.04% | 48.42% | 63.80% | 47.68% | 12.55% | 0.00% | 0.00% | -22,416.45% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.86M | 811.86K | 672.21K | 60.95K | 15.20K | 12.80K | 0.00 | 32.79K | 8.66K | 327.00K | 137.40K | 1.83K | 142.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 10.10M | 8.90M | 1.87M | 547.42K | 622.73K | 1.21M | 850.56K | 899.58K | 769.08K | 1.32M | 1.80M | 704.85K | 413.55K | 537.38K | 0.00 | 24.08K | 0.00 |
| Selling & Marketing | 734.25K | 578.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 105.00K | 0.00 | 0.00 | 0.00 | 0.00 | 20.00 | 2.00K | 0.00 |
| SG&A | 10.83M | 9.48M | 1.87M | 547.42K | 622.73K | 1.21M | 850.56K | 899.58K | 769.08K | 1.43M | 1.80M | 704.85K | 413.55K | 537.38K | 20.00 | 26.08K | 13.12K |
| Other Expenses | 438.88K | 80.40K | 12.74K | 14.07K | 13.77K | -871.73K | -76.93K | 60.73K | 4.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.12M | 10.37M | 2.55M | 622.44K | 651.71K | 1.22M | 857.19K | 993.11K | 781.99K | 1.76M | 1.94M | 706.68K | 556.20K | 537.38K | 20.00 | 26.08K | 13.12K |
| Cost & Expenses | 28.88M | 13.02M | 2.67M | 648.28K | 662.76K | 1.61M | 857.19K | 993.11K | 781.99K | 1.76M | 1.94M | 706.68K | 556.20K | 537.38K | 20.00 | 26.08K | 13.12K |
| Interest Income | 811.97K | 518.65K | 328.82K | 168.11K | 115.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 137.31K | 39.41K | 328.82K | 168.11K | 115.90K | 159.42K | 104.83K | 34.73K | 307.21K | 179.10K | 6.46K | 1.27K | 0.00 | 0.00 | 0.00 | 5.03K | -13.12K |
| Depreciation & Amortization | 149.15K | 25.16K | 12.74K | 14.07K | 13.77K | 49.36K | 6.63K | 60.73K | 4.25K | 1.75M | 1.93M | 703.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -3.82M | -26.45M | -12.09M | -2.60M | -948.38K | -1.95M | -928.78K | -932.38K | -1.34M | -9.77K | -555.03K | -4.56K | -556.20K | -537.38K | -1.20M | -26.08K | -13.12K |
| EBITDA Ratio | -15.87% | -187.09% | -1,062.66% | -3,665.20% | -4,462.92% | -444.75% | 0.00% | 0.00% | -45,434.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.79M | -8.67M | -2.44M | -576.87K | -641.64K | -1.17M | -857.19K | -993.11K | -780.28K | -1.76M | -1.94M | -706.68K | -556.20K | -537.38K | -15.65K | -26.08K | -13.12K |
| Operating Income Ratio | -19.86% | -199.60% | -1,068.24% | -807.83% | -3,037.91% | -260.85% | 0.00% | 0.00% | -45,683.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 674.42K | 489.61K | -10.00M | -2.21M | -436.42K | -989.62K | -183.05K | -2.50M | -872.63K | -179.10K | -555.41K | -1.27K | 0.00 | 0.00 | -1.19M | 0.00 | 0.00 |
| Income Before Tax | -4.11M | -26.51M | -12.44M | -2.78M | -1.08M | -2.16M | -1.04M | -3.50M | -1.65M | -1.93M | -2.49M | -707.95K | 0.00 | -537.38K | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -17.06% | -610.07% | -5,444.41% | -3,898.74% | -5,104.18% | -482.15% | 0.00% | 0.00% | -96,774.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 395.17K | 233.30K | 328.82K | -1.89M | 383.39K | -41.53K | 1.29K | 2.47M | 565.42K | -1.75M | 548.95K | -703.39K | 556.20K | 0.00 | 0.00 | 31.11K | 13.12K |
| Net Income | -4.51M | -26.74M | -12.77M | -897.68K | -1.46M | -2.16M | -1.04M | -3.50M | -1.65M | -1.93M | -2.49M | -707.95K | -556.20K | -537.38K | 0.00 | -31.11K | -13.12K |
| Net Income Ratio | -18.70% | -615.44% | -5,588.36% | -1,257.08% | -6,919.37% | -482.15% | 0.00% | 0.00% | -96,774.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -370.41 | -3.52K | -9.77K | -1.04K | -828.01 | -141.54 | -23.84 | -164.63 | -270.44 | -526.17 | -827.19 | -275.68 | -228.33 | -350.77 | 0.00 | -66.46 | -28.04 |
| EPS Diluted | -370.41 | -3.52K | -9.77K | -1.04K | -828.01 | -141.54 | -23.84 | -164.63 | -270.44 | -526.17 | -827.19 | -275.68 | -228.33 | -350.77 | 0.00 | -66.46 | -28.04 |
| Weighted Avg Shares Out | 12.17K | 7.59K | 1.31K | 866.00 | 1.77K | 15.23K | 43.63K | 21.24K | 1.53K | 3.68K | 3.01K | 2.57K | 2.44K | 1.53K | 23.47K | 468.00 | 468.00 |
| Weighted Avg Shares Out (Dil) | 12.17K | 7.59K | 1.31K | 866.00 | 1.77K | 15.23K | 43.63K | 21.24K | 1.53K | 3.68K | 3.01K | 2.57K | 2.44K | 1.53K | 23.47K | 468.00 | 468.00 |
Source: https://incomestatements.info
Category: Stock Reports